Raynaud's Phenomenon
10
0
0
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
10.0%
1 terminated out of 10 trials
88.9%
+2.4% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (10)
Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon
The Effects of Exercise in Patients With Systemic Sclerosis
A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)
"As Required" Oral Sildenafil in Raynaud's Phenomenon
Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands
Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon
MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison
A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
The Effect of Physical Therapy on Raynaud's Phenomenon Secondary to Systemic Sclerosis
Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon